APGE (STOCKS)
Apogee Therapeutics, Inc. Common Stock
$86.740000
+0.470000 (+0.54%)
Prev close: $86.270000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Michael Henderson
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6,021.59M
- Employees
- 196
- P/E (TTM)
- -20.58
- P/B (TTM)
- 6.56
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $285.60M |
| Research and Development | $214.71M |
| Other Operating Expenses | $70.88M |
| Operating Income/Loss | -$285.60M |
| Income/Loss From Continuing Operations After Tax | -$255.84M |
| Income/Loss From Continuing Operations Before Tax | -$255.57M |
| Income Tax Expense/Benefit | $278.00K |
| Income Tax Expense/Benefit, Current | $278.00K |
| Net Income/Loss | -$255.84M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$255.84M |
| Net Income/Loss Available To Common Stockholders, Basic | -$255.84M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.22 |
| Diluted Earnings Per Share | -$4.22 |
| Basic Average Shares | 60,690,820 |
| Diluted Average Shares | 60,690,820 |
| Assets | $937.13M |
| Current Assets | $741.36M |
| Noncurrent Assets | $195.78M |
| Fixed Assets | $5.69M |
| Other Non-current Assets | $190.09M |
| Liabilities | $33.25M |
| Current Liabilities | $27.91M |
| Accounts Payable | $1.22M |
| Wages | $3.66M |
| Other Current Liabilities | $23.03M |
| Noncurrent Liabilities | $5.35M |
| Equity | $903.88M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $903.88M |
| Liabilities And Equity | $937.13M |
| Net Cash Flow From Operating Activities | -$227.45M |
| Net Cash Flow From Operating Activities, Continuing | -$227.45M |
| Net Cash Flow From Investing Activities | -$179.57M |
| Net Cash Flow From Investing Activities, Continuing | -$179.57M |
| Net Cash Flow From Financing Activities | $396.49M |
| Net Cash Flow From Financing Activities, Continuing | $396.49M |
| Net Cash Flow | -$10.53M |
| Net Cash Flow, Continuing | -$10.53M |
| Comprehensive Income/Loss | -$255.68M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$255.68M |
| Other Comprehensive Income/Loss | $165.00K |